

80.US2.ST25  
SEQUENCE LISTING

<110> Jung, Jae-Kyu  
Semple, Graeme  
Johnson, Benjamin R

<120> 4-Oxo-4,5-dihydro-furan-2-carboxylic acid DERIVATIVES AND METHODS  
OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF

<130> 80.US2.PCT

<150> 60/524,269  
<151> 2003-11-21

<160> 2

<170> PatentIn version 3.2

<210> 1  
<211> 1092  
<212> DNA  
<213> Homo sapien

<400> 1  
atgaatcggc accatctgca ggatcaactt ctggaaatag acaagaagaa ctgctgttg 60  
ttccgagatg acttcattgt caaggtgttgcggccgtgt tggggctgga gtttatcttc 120  
gggcttctgg gcaatggcct tgccctgtgg attttctgtt tccacactaa gtcctggaaa 180  
tccagccgga tttccctgtt caacctggca gtggctgact ttctactgat catctgcctg 240  
cccttcctga tggacaacta tgtgaggcgt tggactgga agtttgggaa catcccttgc 300  
cggtgtatgc tcttcatgtt ggctatgaac cgccaggca gcatcatctt cctcacgtg 360  
gtggcggtag acaggtattt cgggtggtc catccccacc acgcctgaa caagatctcc 420  
aatcggacag cagccatcat ctctgcctt ctgtggggca tcactattgg cctgacagtc 480  
cacctcctga agaagaagat gccgatccag aatggcggtg caaatttgtg cagcagcttc 540  
agcatctgcc ataccttcca gtggcacgaa gccatgttcc tcctggagtt cttcctgccc 600  
ctgggcatca tcctgttctg ctcagccaga attatctgga gcctgcggca gagacaaatg 660  
gaccggcatg ccaagatcaa gagagccatc accttcatca tgggtgtggc catcgcttt 720  
gtcatctgct tcctccca cgtgggtgtg cggatccgca tcttctggct cctgcacact 780  
tcgggacgc agaattgtga agtgtaccgc tcgggtggacc tggcgttctt tatcactctc 840  
agcttccac acatgaacag catgctggac cccgtgggtgt actacttctc cagcccatcc 900  
tttcccaact tcttctccac tttgatcaac cgctgcctcc agaggaagat gacaggtgag 960  
ccagataata accgcagcac gagcgtcgag ctcacagggg accccaacaa aaccagaggc 1020  
gctccagagg cgtaatggc caactccggt gagccatgga gccccttta tctggccca 1080  
acctctccctt aa 1092

## 80.US2.ST25

<210> 2  
<211> 363  
<212> PRT  
<213> Homo sapien

<400> 2

Met Asn Arg His His Leu Gln Asp His Phe Leu Glu Ile Asp Lys Lys  
1 5 10 15

Asn Cys Cys Val Phe Arg Asp Asp Phe Ile Val Lys Val Leu Pro Pro  
20 25 30

Val Leu Gly Leu Glu Phe Ile Phe Gly Leu Leu Gly Asn Gly Leu Ala  
35 40 45

Leu Trp Ile Phe Cys Phe His Leu Lys Ser Trp Lys Ser Ser Arg Ile  
50 55 60

Phe Leu Phe Asn Leu Ala Val Ala Asp Phe Leu Leu Ile Ile Cys Leu  
65 70 75 80

Pro Phe Leu Met Asp Asn Tyr Val Arg Arg Trp Asp Trp Lys Phe Gly  
85 90 95

Asp Ile Pro Cys Arg Leu Met Leu Phe Met Leu Ala Met Asn Arg Gln  
100 105 110

Gly Ser Ile Ile Phe Leu Thr Val Val Ala Val Asp Arg Tyr Phe Arg  
115 120 125

Val Val His Pro His His Ala Leu Asn Lys Ile Ser Asn Arg Thr Ala  
130 135 140

Ala Ile Ile Ser Cys Leu Leu Trp Gly Ile Thr Ile Gly Leu Thr Val  
145 150 155 160

His Leu Leu Lys Lys Lys Met Pro Ile Gln Asn Gly Gly Ala Asn Leu  
165 170 175

Cys Ser Ser Phe Ser Ile Cys His Thr Phe Gln Trp His Glu Ala Met  
180 185 190

Phe Leu Leu Glu Phe Phe Leu Pro Leu Gly Ile Ile Leu Phe Cys Ser  
195 200 205

Ala Arg Ile Ile Trp Ser Leu Arg Gln Arg Gln Met Asp Arg His Ala  
210 215 220

80.US2.ST25

Lys Ile Lys Arg Ala Ile Thr Phe Ile Met Val Val Ala Ile Val Phe  
225 230 235 240

Val Ile Cys Phe Leu Pro Ser Val Val Val Arg Ile Arg Ile Phe Trp  
245 250 255

Leu Leu His Thr Ser Gly Thr Gln Asn Cys Glu Val Tyr Arg Ser Val  
260 265 270

Asp Leu Ala Phe Phe Ile Thr Leu Ser Phe Thr Tyr Met Asn Ser Met  
275 280 285

Leu Asp Pro Val Val Tyr Tyr Phe Ser Ser Pro Ser Phe Pro Asn Phe  
290 295 300

Phe Ser Thr Leu Ile Asn Arg Cys Leu Gln Arg Lys Met Thr Gly Glu  
305 310 315 320

Pro Asp Asn Asn Arg Ser Thr Ser Val Glu Leu Thr Gly Asp Pro Asn  
325 330 335

Lys Thr Arg Gly Ala Pro Glu Ala Leu Met Ala Asn Ser Gly Glu Pro  
340 345 350

Trp Ser Pro Ser Tyr Leu Gly Pro Thr Ser Pro  
355 360